leadf
logo-loader
viewMGC Pharmaceuticals Ltd
(
LSE:MXCOTC:MGCLFFRA:H5OASX:MXC
)

MGC Pharmaceuticals' recruit first patient to phase III trial in those hospitalised with COVID-19

MGC Pharmaceuticals Ltd (ASX:MXC, LON:MXC) Dr. Nadya Lisovoder, our Chief Medical Officer joins Proactive to explain the importance of the recruitment of its first patient to a phase III trial of its cannabis-derived drug in patients hospitalised with COVID-19.

Lisovoder explains that there are more than 250 people who will take part in the double-blind, placebo-controlled efficacy and safety evaluation of CimetrA following initial dosing at the Rambam Medical Center in Israel.

Quick facts: MGC Pharmaceuticals Ltd

Follow
LSE:MXC

Price: 3.1 GBX

Market Cap: £73.93 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

MGC Pharmaceuticals: Continuous global breakthroughs as progress accelerates

Proactive Research Analyst Ed Stacey presents his analysis on MGC Pharmaceuticals (LON:MXC).  The company recently announced that it has received a UK import permit for CannEpil+, which is MGC’s cannabis-derived therapy for refractory epilepsy, to be used initially on a compassionate access...

1 week, 3 days ago

2 min read